These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35441836)

  • 1. Real-life experience of hepatitis C treatment in a Spanish prison.
    Tejera-Pérez RJ; Iglesias-Gómez A; Oliva-Oliva A; Rodríguez-Alonso B; Alonso-Sardón M; Sánchez Ledesma M; Carbonell-Muñoz C; Pendones Ulerio J; Muñoz-Bellido JL; Belhassen-García M
    Rev Esp Quimioter; 2022 Jun; 35(3):273-278. PubMed ID: 35441836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of hepatitis C virus in a prison: An 18-year experience.
    Nogales-Garcia M; Parraza Diez N; Vargas Axpe A; Velasco Garcia R; Larrabeiti-Etxebarria A; Roy Lopez-Cano I; Atrio Alvarez I; Lopez de Arcaute Trincado A; Fernandez Lopez de Vicuña EM; Saez de Adana Arroniz E; Martínez Martínez C; Portu Zapirain J
    Enferm Infecc Microbiol Clin (Engl Ed); 2024 May; 42(5):236-241. PubMed ID: 37117143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study.
    Marco A; Antón JJ; Trujols J; Saíz de la Hoya P; de Juan J; Faraco I; Caylà JA;
    BMC Infect Dis; 2015 Aug; 15():355. PubMed ID: 26286450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic Hepatitis C Cascade of Care in Prisoners-Is There Still Some Work to Do? Analysis of Two Large Penitentiaries in Northern Italy.
    Cambianica A; Marchese V; Pennati F; Faustinelli A; Migliorati M; Roda F; Spinetti A; Zaltron S; Fiorentini S; Caruso A; Quiros-Roldan E; Castelli F; Focà E
    Int J Environ Res Public Health; 2024 Jan; 21(1):. PubMed ID: 38248566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era.
    Hariri S; Sharafi H; Sheikh M; Merat S; Hashemi F; Azimian F; Tamadoni B; Ramazani R; Gouya MM; Abbasi B; Tashakorian M; Alasvand R; Alavian SM; Poustchi H; Malekzadeh R
    Harm Reduct J; 2020 Oct; 17(1):80. PubMed ID: 33081794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of direct-acting antiviral regimens and telemedicine on the treatment of inmates with hepatitis C virus infection in Israeli prisons.
    Richter V; Goldstein L; Cohen DL; Bermont A; Zelnik Yovel D; Madar M; Rabinovitch R; Shirin H; Broide E
    Sci Prog; 2022; 105(2):368504221105173. PubMed ID: 35722762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002-2016.
    Marco A; Guerrero RA; Vergara M; Gallego C; Solé C; Planella R; Vaz ME; Teixidó N; Sastre A; Touzón C; da Silva A; Almada G; Ruíz A; Caylà JA; Turu E
    Int J Drug Policy; 2019 Oct; 72():189-194. PubMed ID: 31160156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
    Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
    Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
    Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
    J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
    Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
    Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus infection and its associated factors among prisoners in a Nigerian prison.
    Okafor IM; Ugwu SO; Okoroiwu HU
    BMC Gastroenterol; 2020 Oct; 20(1):360. PubMed ID: 33126856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
    Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
    Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study.
    Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B;
    Clin Infect Dis; 2022 Nov; 75(10):1809-1819. PubMed ID: 35362522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C hospitalizations in Spain and impact of new curative antiviral therapies.
    Ramos-Rincon JM; Pinargote-Celorio H; de Mendoza C; Ramos-Belinchón C; Barreiro P; Gómez-Gallego F; Corral O; Soriano V
    J Viral Hepat; 2022 Sep; 29(9):777-784. PubMed ID: 35643914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
    Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
    BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of hepatitis C in the haemophiliac population in Ireland, after 30 years of infection in the pre-DAA treatment era.
    Murphy N; O'Mahony B; Flanagan P; Noone D; White B; Bergin C; Norris S; Thornton L;
    Haemophilia; 2017 Sep; 23(5):712-720. PubMed ID: 28752601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment effectiveness and side effects of patients with hepatitis C in the prisons of Southern Taiwan: a real-life retrospective analysis.
    Tsai YC; Yu ML; Ko CY; Hsin YH; Tsai QZ; Huang CW
    BMJ Open; 2023 Jun; 13(6):e070490. PubMed ID: 37286314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consensus recommendations on the management of hepatitis C in Australia's prisons.
    Winter RJ; Sheehan Y; Papaluca T; Macdonald GA; Rowland J; Colman A; Stoove M; Lloyd AR; Thompson AJ
    Med J Aust; 2023 Mar; 218(5):231-237. PubMed ID: 36871200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Health Outcomes from Hepatitis C Treatment Scale-Up in Spain's Prisons: A Cost-Effectiveness Study.
    Dalgic OO; Samur S; Spaulding AC; Llerena S; Cobo C; Ayer T; Roberts MS; Crespo J; Chhatwal J
    Sci Rep; 2019 Nov; 9(1):16849. PubMed ID: 31727921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.